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Abstract
Background: Kinin B1 receptors are inducible molecules up-regulated after inflammatory stimuli. This study
evaluated the relevance of kinin B1 receptors in a mouse depression behavior model.
Methods: Mice were exposed to a 5-min swimming session, and 30 min later they were injected with E. coli
lipopolysaccharide (LPS). Depression-like behavior was assessed by determining immobility time in a tail suspension
test. Different brain structures were collected for molecular and immunohistochemical studies. Anhedonia was
assessed by means of a sucrose intake test.
Results: Our protocol elicited an increase in depression-like behavior in CF1 mice, as assessed by the tail-
suspension test, at 24 h. This behavior was significantly reduced by treatment with the selective B1 receptor
antagonists R-715 and SSR240612. Administration of SSR240612 also prevented an increase in number of activated
microglial cells in mouse hippocampus, but did not affect a reduction in expression of mRNA for brain-derived
neurotrophic factor. The increased immobility time following LPS treatment was preceded by an enhancement of
hippocampal and cortical B1 receptor mRNA expression (which were maximal at 1 h), and a marked production of
TNFa in serum, brain and cerebrospinal fluid (between 1 and 6 h). The depression-like behavior was virtually
abolished in TNFa p55 receptor-knockout mice, and increased B1 receptor mRNA expression was completely
absent in this mouse strain. Furthermore, treatment with SSR240612 was also effective in preventing anhedonia in
LPS-treated mice, as assessed using a sucrose preference test.
Conclusion: Our data show, for the first time, involvement of kinin B1 receptors in depressive behavioral responses,
in a process likely associated with microglial activation and TNFa production. Thus, selective and orally active B1
receptor antagonists might well represent promising pharmacological tools for depression therapy.
Background
Chronic depression represents a public health worldwide
problem. Despite the existence of several drugs for
depression treatment, these medicines have many signif-
icant adverse effects, and many patients do not display
satisfactory responses to the current therapeutic arsenal
[1]. The etiology of depression is incompletely under-
stood, and this precludes development of more effective
drugs. Compelling literature data suggests a crosstalk
between immunological changes and major depression
[2,3]. It has been demonstrated that systemic adminis-
tration of pro-inflammatory cytokines or some bacterial
products to rodents elicits a condition described as sick-
ness behavior, characterized by decreased food con-
sumption and locomotor activity, social isolation, and
changes in the circadian cycle, which is followed by
depressive behavior [3-5].
Toll-like receptors (TLR) are recognition units that
distinguish microbial structures. Gram-negative bacterial
lipopolysaccharide (LPS) commonly signals through
TLR4, leading to activation of several intracellular path-
ways [6]. It has been demonstrated that depression-like
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cytokine production; importantly, depressed patients dis-
play elevated cytokine plasma levels [2,3]. Furthermore,
it has been recently shown that TLR activation following
infection can induce systemic inflammation, accompa-
nied by signs of brain-controlled illness in rats [7,8].
Kinins are a group of peptides that are rapidly gener-
ated in response to several stimuli [9]. Once released,
kinins activate two G protein-coupled receptors, called
B1 and B2.B 2 receptors are constitutively expressed
throughout several tissues, whereas B1 receptors are not
commonly expressed under normal conditions, although
they are rapidly upregulated after infection, trauma, or
by certain cytokines [10-13]. Of relevance, a series of
previous publications has demonstrated an important
role for TNFa in the up-regulation of kinin B1 receptors
[14-17]. Therefore, B1 receptors are likely induced under
certain pathological conditions, being involved in several
chronic inflammatory and pain processes [9,10].
Previous studies have demonstrated that LPS from
either E. coli or P. gingivalis can induce a marked up-reg-
ulation of kinin B1 receptors in animal models of periph-
eral inflammation, via cytokine production [14,15,18]. Of
relevance, recent studies also suggest that kinin B1 recep-
tors have also been implicated in some diseases involving
the central nervous system (CNS), such as epilepsy,
Alzheimer’s disease and neuropathic pain [19-21]. Taking
into account the above mentioned data, the present study
was designed to test the hypothesis that kinin B1 recep-
tors might be implicated in depression-like behavioral
changes elicited by systemic administration of E. coli
LPS, in mice submitted to a previous stressing forced
swimming session. This experimental protocol was based
on the concept that internal and external stressors are
able to interact, culminating in a general illness state,
which causes an allostatic overload [2,22,23]. Efforts have
also been made to define some of the mechanisms
responsible for B1 receptor induction in the context of
LPS-treated depressed animals by using biochemical and
molecular techniques, such as flow cytometry, ELISA and
real-time PCR. We have also aimed at determining
whether antagonism of kinin B1 receptors could modu-
late glial activity, throughout immunohistochemical stu-
dies. Finally, we further investigated the role played by
TNFa in the depressive-like behavior in our experimental
paradigm, by using TNFa p55 receptor-deficient mice.
Methods
Materials
The following drugs and reagents were used: imipramine,
LPS from E. coli serotype 0111:B4, aprotinin A, benzetho-
nium chloride, EDTA, HTAB, hydrogen peroxide, PMSF,
TMB and Tween-20 (all from Sigma Chemical Company
St. Louis, U.S.A); R-715, kindly provided by Dr. Domenico
Regoli (University of Sherbrooke, Sherbooke, Quebec,
Canada); SSR240612 was kindly provided by Sanofi-
Synthelabo Recherche (Montpellier, France). FR173657
was donated by Fournier Laboratories (Dijon, France). The
stock solutions of the drugs were prepared in PBS in sili-
conized plastic tubes, maintained at -18°C, and diluted to
the desired concentration just before use.
Animals
Male CF1 and C57/BL6 wild-type, or TNFa p55 receptor
knockout mice (25 to 30 g) were used in this study. Ani-
mals were housed under conditions of optimum light,
temperature and humidity (12 h light-dark cycle, 22 ± 1°C,
under 60 to 80% humidity), with food and water provided
ad libitum. CF1 mice were obtained from the central ani-
mal house of the Universidade Federal de Pelotas (UFPEL,
Brazil). C57/BL6 wild-type, or TNFa p55 receptor knock-
out mice were supplied by the Universidade Federal de
Minas Gerais (UFMG, Belo Horizonte, Brazil). All experi-
ments were performed between 08:00 AM and 08:00 PM.
Experiments were conducted in accordance with current
guidelines for the care of laboratory animals and ethical
guidelines for the investigation of experimental pain in
conscious animals laid down by Zimmermann (1983) [24].
All the experimental procedures were approved by the
Animal Ethics Committees of Universidade Federal de
Santa Catarina (SC) and Pontifícia Universidade Católica
do Rio Grande do Sul (RS).
Induction of depressive-like behavior
As a pre-stressful stimulus, the animals were subjected
to forced swimming for 5 min, in a water temperature
of 23 ± 1°C. Subsequently, they were injected with LPS
from E. coli (serotype 0111:B4) at the doses of 450 mg/
kg (CF1 mice) or 1000 μg/kg (C57/BL6 wild-type, or
TNFa p 5 5r e c e p t o rk n o c k o u tm i c e ) ,b yi . p .r o u t e .T h e
control groups received saline (0.9% NaCl solution,
10 ml/kg, i.p.). The protocol of forced swimming and
the selected doses of LPS were determined on the basis
of pilot experiments (not shown).
The animals were assessed in behavioral paradigms at
6, 24 or 48 h time points after LPS administration,
depending on the experimental protocol. All the beha-
vioral parameters were evaluated by trained experimen-
ters blind to the treatment groups. Separate groups of
mice were euthanized at different time-points after LPS
injection, in order to perform biochemical, molecular
biology and immunohistochemical assays, as described
in the next sections.
Protocols of treatment with kinin antagonists
To verify the involvement of kinin receptors in the beha-
vioral changes elicited by LPS from E. coli, the animals
were treated with one of the following drugs before
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receptor SSR240612 (5 mg/kg, i.p., 30 min; or 10 mg/kg,
p.o., 1 h) or R-715 (0.5 mg/kg, i.p., 30 min), or the selec-
tive kinin B2 receptor antagonist FR173657 (30 mg/kg,
i.p., 30 min). The classical tricyclic antidepressant imipra-
mine (10 mg/kg, i.p., 30 min) was used as a positive con-
trol drug. Control animals received saline solution (0.9%
NaCl solution, 10 ml/kg), at the corresponding schedules
of treatment used for the antagonists. For molecular biol-
ogy and immunohistochemical studies, animals were
treated with SSR240612 (5 mg/kg, i.p.), 30 min before
LPS, and were sacrificed at defined time-points as
described in the next sections. The doses of kinin antago-
nists and imipramine were determined on the basis of
previous publications [25-27].
Tail-suspension test
To assess the depression-like behavior following the
5-min forced swimming session in animals treated with
LPS from E. coli, we employed a tail-suspension model
according to the methodology originally described by
Steru et al. (1985) [28]. At different time intervals after
LPS treatment (6, 24 or 48 h), the animals were sus-
pended 50 cm above the floor by means of an adhesive
tape, placed approximately 1 cm from the tip of the tail.
The time during which mice remained immobile was
quantified (in s) over a period of 6 min.
Sucrose consumption test
Anhedonia represents decreased sensation of pleasure,
which can be evaluated in mice by measuring reduction
of sucrose intake. The protocol used in our study was
adapted from the method described by Strakaliva et al,
2004 [29]. For three days, mice received 1% sucrose
solution, and they were subjected to forced swimming,
twice a day, for a total of six sessions (temperature
water 16 to 19°C, for 5 min), as a pre-stressful stimuli.
After the last swimming session, mice were treated with
LPS from E. coli (450 μg/kg, i.p), followed by a 24-h
period of food and water deprivation, according to the
original protocol [29]. Sucrose intake was assessed for
12 h, where mice had free access to two bottles, one
with 1% sucrose solution and another with tap water.
The weight differences of bottles were used to calculate
the consumption of sucrose with the following formula:
% sucrose intake = [sucrose intake (g)] × 100/[sucrose
intake (g) + tap water (g)]. The animals were treated
with the selective kinin B1 receptor antagonist
SSR240612 (10 mg/kg, p.o., 1 h) or the antidepressant
imipramine (10 mg/kg, i.p., 30 min), both administered
before LPS injection. Control animals received saline
solution, at same schedule of treatment.
Open-field test
To analyze the effects of swimming session plus LPS
treatment on the locomotor activity, the animals were
evaluated in an open-field test [30], 6 or 24 h after
endotoxin administration. The experiments were con-
ducted in a sound-attenuated room, under low-intensity
light. Mice were individually placed in the centre of an
acrylic box (40 × 60 × 50 cm), with the floor divided
into 9 squares. The number of squares crossed with the
four paws was registered over a period of 6 min.
Body temperature assessment
Mouse colonic temperature was recorded using a com-
mercially available thermometer (Pro-check®), which was
dipped in Vaseline and inserted about 0.5 cm into a
gently hand-restrained mouse. After recording the initial
colonic temperature (t = 0), the body temperature of
mice was evaluated 6 or 24 h after LPS injection.
Real-time PCR quantification of kinin B1 receptor and
BDNF mRNA
Mouse hippocampi and cortex were collected using a
special apparatus, after euthanasia by decapitation, at 1,
3, 6 and 24 h following LPS injection. Total RNA was
extracted using Trizol reagent (Invitrogen), according to
the manufacturer’s instructions. The concentration of
total RNA was determined by measuring the absorbance
at 260 nm. In order to obtain the reverse transcript
(cDNA), 2 μg of total RNA were reverse transcribed
using oligo(dT) as a primer (0.05 μg), 50 U of reverse
transcriptase (Promega), dNTP (144 μM; Promega),
reaction buffer [10 mM dithiothreitol (DTT), 3 mM
MgCl2, 75 mM KCl, and 50 mM Tris-HCl, pH 8.3], and
2 U of RNAsin Plus (Promega), in a final volume of
12.5 μl. The cDNA was obtained after incubation of the
samples for 5 min at 70°C, 4°C for 5 min, 37°C for
60 min, 70°C for 5 min, and 4°C for 5 min.
B1 receptor and BDNF mRNA expression was carried
out through fluorescence-based real-time PCR. To this
end, approximately 100 ng of cDNA were amplified in
duplicates using TaqMan-based chemistry with specific
primers and FAM-labeled probes for mouse BDNF (cat#
Mm00432069_m1), B1 receptor (cat# Mm00432059_s1)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
cat# Mm03302249_g1) as the endogenous control for nor-
malization. Amplifications were carried out in a Thermal-
cycler (StepOne Plus, Applied Biosystems) for 50 cycles;
the fluorescence was collected at each amplification cycle
and the data analyzed using the 2
-ΔΔCt method for relative
quantification. Expression of the target genes was cali-
brated against conditions found in naive animals, i.e., non-
treated mice.
Viana et al. Journal of Neuroinflammation 2010, 7:98
http://www.jneuroinflammation.com/content/7/1/98
Page 3 of 12Immunohistochemical studies
Brain samples were collected 24 h following LPS treat-
ment, and fixed in a phosphate buffered saline (PBS)
solution containing 4% paraformaldehyde for 24 h at
room temperature. Subsequently, the samples were sub-
mitted to standard histological proceeding in order to
be embedded in paraffin. Hippocampus sections were
cut approximately at the level of 3 mm from bregma
[2,31]. To determine glial activity, immunohistochemis-
try was carried out on paraffin tissue sections using
CD68 antibody (1:150; Cell Signaling Technology, Bev-
erly, MA, USA). Following quenching of endogenous
peroxidase with 1.5% hydrogen peroxide in methanol for
20 min, high temperature antigen retrieval was per-
formed by immersion of the slides in a water bath at 95
to 98°C in 10 mM trisodium citrate buffer pH 6.0, for
45 min. After overnight incubation at 4°C with the pri-
mary antibody, the slides were washed with PBS, incu-
bated with the appropriate biotinylated secondary
antibody (Dako Cytomation), and then processed using
the Streptavidin-HRP reagent (Dako Cytomation),
according to the manufacturer’s instructions. Sections
were developed with DAB (3,3’-diaminobenzidine)
(Dako Cytomation) in chromogen solution and counter-
stained with Harris’s hematoxylin. Control and experi-
mental tissues were placed on the same slide and
processed under the same conditions.
Images were acquired by Sight DS-5M-L1 digital cam-
era connected to a light microscope Eclipse - 80i
(Nikon). Settings for image acquisition were identical for
control and experimental tissues. For each mouse, the
number of CD-68 positive cells was counted in four dif-
ferent fields of CA1, CA2, CA3 and dentate girus (DG)
hippocampal sub regions, using 40X magnification.
Measurement of TNFa levels by ELISA
The animals were submitted to forced swimming and
treated with LPS from E. coli, as described before. Sub-
sequently, they were euthanized by decapitation at dis-
tinct intervals of time following LPS (1, 3, 6, 12 and
24 h). TNFa levels were determined in serum or in
whole brain by means of a standard sandwich ELISA
technique, according to the recommendations of the
supplier (R&D Systems, USA). For the brain assays, the
tissues were removed and placed in a PBS solution con-
taining 0.05% Tween 20, 0.1 mM PMSF, 0.1 mM benza-
methonium chloride, 10 mM EDTA, 2 μg/ml aprotinin
A, and 0.5% BSA. The mouse brains were homogenized
and then centrifuged at 3,000× g for 10 min, and the
supernatant was employed for ELISA analysis.
2.10. Preparation of samples for flow cytometry
Cerebral spinal fluid (CSF) samples were taken from the
cisterna magna using a method adapted from Liu and
Duff [32]. Mice were submitted to forced swimming and
treated with LPS from E. coli (450 μg / k g ,i . p . ) ,a s
described before. One, three or twenty four h after treat-
ment, mice were anesthetized with a mixture of keta-
mine (100 mg/kg; i.p.) and xylazine (10 mg/kg; i.p.), and
placed on stereotaxic instrument. The head was posi-
tioned in a 135° angle with the body, and a sagittal inci-
sion of the skin was made inferior to the occiput. To
aspirate the CSF, the metal part of an insulin needle was
adapted at one end of a polyethylene 50 tubing, and at
the other end a 50 μl Hamilton syringe was attached.
The needle was attached to the bottom end of the
manipulator bar, and 3 mm of it was inserted into the
cisterna magna. The CSF collected was transferred to a
0.5 ml Eppendorf tube, and frozen immediately on dry
ice and then kept into -80°C until use. CSF from naïve
animals was used as control.
Flow cytometer acquisition and data analysis
The BD Cytometric Bead Array (CBA) was used to
quantitatively measure cytokines in the CSF. The CBA
Mouse Inflammation Kit® (BD Bioscience, San Jose, CA)
was used according to the manufacturer’s instructions
to simultaneously detect interleukin-6 (IL-6), interleu-
kin-10 (IL-10), interferon-g (IFN-g), tumor necrosis fac-
tor alpha (TNFa), and interleukin-12p70 (IL-12p70).
Flow cytometer readings were performed using FACS-
Canto II red laser in a medium range of 633 nm. Data
were acquired using FACSDiva software and analyzed
using FCAP Array software (all from BD Bioscience).
The captured cytokines were detected via direct immu-
noassay using six different antibodies coupled to phy-
coerythrin (PE). Standard curves were generated for
each cytokine using the mixed cytokine beads standard
provided by the kit. The concentration of the standards
ranged from 20 to 5000 pg/ml. Five standard curves
were plotted such as: cytokine concentration X mean
fluorescence intensity (MFI), using a four-parameter
logistic curve fitting model. The concentrations of each
CSF cytokine were determined from these four-para-
meter equations using the MFI value of each cytokine. If
a sample had a cytokine concentration below the detec-
tion limit for the assay, a value of 0 was assigned for
that concentration.
Statistical analysis
For the behavioral parameters and Elisa protocols, the
results are presented as the mean ± SEM of 6 to 8 ani-
mals. For the real-time PCR, flow cytometry and immu-
nohistochemical experiments, the results are given as
the mean ± SEM of 4 independent experiments, per-
formed in triplicate. The statistical comparison between
these values was performed by one-way analysis of var-
iance followed by Newman-Keuls post hoc test. P values
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The results depicted in Figure 1a demonstrate that sys-
temic administration of E. coli LPS (450 μg/kg, i.p.),
following a 5-min forced swimming session, elicited
time-related depression-like behavior in mice, accord-
ing to assessment in the tail-suspension paradigm. The
increase of immobility time in animals pre-treated with
LPS was statistically significant at 24 h (P < 0.01), but
not at 6 h (P > 0.05; results not shown), returning to
control levels at 48 h (P <0 . 0 5 ) ,i nc o m p a r i s o nt os a l -
ine-treated mice. As could be expected, treatment with
the classical antidepressant drug imipramine (10 mg/
kg, i.p.), given 30 min before the behavioral assess-
ment, produced a marked reduction of the immobility
time (47 ± 16% of reduction; Figure 1a). Of interest,
i.p. treatment with the selective B1 receptor antagonists
R-715 (0.5 mg/kg, 30 min) or SSR240612 (5 mg/kg,
i.p., 30 min), or even oral administration of SSR240612
(10 mg/kg, 1 h), caused a significant inhibition of
depression-like behavior induced by LPS (Figure 1c).
The percentages of inhibition for animals treated with
B1 receptor antagonists were: 46 ± 6%, 33 ± 7% and
30 ± 6%, respectively. On the other hand, the selective
kinin B2 receptor antagonist FR173657 (30 mg/kg, i.p.,
30 min) failed to significantly alter the immobility time
in our model (P > 0.05; Figure 1b). Injection of LPS
after three days of forced swimming in Swiss mice led
to a significant decrease of sucrose consumption (P <
0.05). The decreased sucrose intake was notably pre-
vented by pre-treating animals with the antidepressant
imipramine (10 mg/kg, i.p., 30 min) or with the B1
receptor antagonist SSR240612 (10 mg/kg, p.o, 1 h)
(P >0 . 0 5 ;F i g u r e1 d ) .
It is well known that LPS treatment evokes some clas-
sical CNS-associated changes in rodents [3-5]. Confirm-
ing literature data, our results demonstrate that E. coli
LPS administration in mice previously submitted to
forced swimming, is able to cause a marked reduction
of body temperature (Figure 1e), and of locomotor activ-
ity when assessed in the open-field arena. The locomo-
tor activity was significantly reduced at 6 h after LPS
(P < 0.05), returning to the control levels at 24 h (Figure
1f). Body temperature was found significantly reduced at
6h( P < 0.01), but not at 24 h after LPS (P >0 . 0 5 ) .
Remarkably, the administration of R-715 (0.5 mg/kg, i.p.),
30 min before the test, did not display any significant
effect on this parameter as assessed at 6 h (Figure 1e).
Considering the oral bioavailability of SSR240612, the
next experiments were carried out using only this
antagonist.
Biochemical and molecular approaches
We wondered whether the effects of selective kinin B1
receptor antagonists might be related to changes of
B1 receptor expression in CNS structures. Therefore, B1
receptor mRNA expression was measured in the hippo-
campus and frontal cortex of mice submitted to a
session of forced swimming, followed by LPS adminis-
tration (450 μg/kg, i.p.). Quantitative real-time experi-
ments revealed a time-dependent, marked increase in B1
receptor mRNA levels in hippocampus, which peaked at
1 h (about 2.5-fold increase) (Figure 2a) while in the
cortex this increase was almost 40 fold 1 h after LPS
treatment (Figure 2b).
As observed in Figure 3, forced swimming followed by
LPS treatment produced a marked increase in CD68
immunoreactivity in mouse hippocampus, indicative of
increased glial cell activation. Of relevance, CD68 label-
ing was almost completely inhibited in animals pre-trea-
ted with the selective kinin B1 receptor antagonist
SSR240612 (5 mg/kg, i.p.), but not by the antidepressant
drug imipramine (10 mg/kg, i.p.), both given 30 min
before LPS. These findings suggest that different
mechanisms appear to mediate imipramine and kinin B1
receptor antagonist antidepressant-like effects. It has
been described that depression is associated with
decreased expression of neurotrophic factors, such as
BDNF [33-35]. In our study, real-time PCR experiments
revealed a marked decrease in BDNF expression in hip-
pocampus of mice submitted to our protocol of depres-
sion, when assessed at both the 6- and the 24-h time-
points (an approximate 50% reduction). However, this
parameter was not significantly affected by pre-treating
animals with the kinin B1 receptor antagonist
SSR240612 (5 mg/kg, i.p., 30 min) (Figure 4).
Next, in order to correlate the changes elicited by LPS
with cytokine production, we assessed levels of TNFa in
whole brain or mouse serum. The animals were submitted
to a forced swimming session and treated with E. coli LPS,
as described above. This series of results showed the
occurrence of a marked, time-dependent increase in
TNFa production, either in brain or in serum of LPS-
treated mice. In serum, TNFa levels peaked between 1
and 3 h (an approximate 90-fold increase), returning to
basal levels 6 h following LPS administration (Figure 5a).
The increase of TNFa in the brain was maximal between
3 and 6 h after LPS (about 1.8-fold augmentation), being
reduced to control values after 12 h (Figure 5b). We also
analyzed cytokine content in CSF from LPS-treated mice,
using flow cytometry analysis. The cytokines IL-6, IL-10,
IFN-g were below detection levels, while the concentration
of IL-12 was similar to that observed in naïve animals
(data not shown). Of interest, CSF TNFa levels peaked 1 h
after LPS injection and remained elevated until 3 h later
(about 340 and 90-fold increase, respectively) (Figure 5c).
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Page 5 of 12Figure 1 Effects of acute inflammation on sickness and depression-like behavior in mice; involvement of kinin B1 receptor. Effect of
systemic administration of E. coli LPS (450 μg/kg, i.p., 24 h and 48 h beforehand) on immobility time in mice submitted to a previous 5-min
swimming session in the tail suspension test (a). Influence of imipramine (10 mg/kg i.p.), given 30 min before, on the increased immobility time
in pre-stressed animals treated with E. coli LPS. (b) Effect of the selective kinin B2 receptor antagonist FR173657 (5 mg/kg, i.p., 30 min). (c) Effect
of the selective kinin B1 receptor antagonists R-715 (0.5 mg/kg, i.p., 30 min) or SSR240612 (5 mg/kg, i.p., 30 min or 10 mg/kg, p.o., 1 h). (d) Effect
of systemic administration of E. coli LPS (450 μg/kg, i.p.) after three days of forced swimming on sucrose intake; influence of imipramine (10 mg/
kg, i.p., 30 min) or SSR240612 (10 mg/kg p.o., 1 h) treatment. (e) Effect of E. coli LPS (450 μg/kg, i.p., 6 h and 24 h) on body temperature, in mice
submitted to a previous 5-min swimming session; influence of treatment with R-715 (0.5 mg/kg, i.p., 30 min). Effect of systemic administration of
E. coli LPS (450 μg/kg, i.p., 6 h and 24 h) on locomotor activity in mice submitted to a previous 5-min swimming session (f). Each column or
point represents the mean of 6-8 animals and vertical lines show the SEM. **P < 0.01 compared to vehicle and
#P < 0.05,
##P < 0.01 compared
LPS-treated mice.
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interrelation between TNFa and B1 receptor upregula-
tion [10,14], we further investigated the role played by
TNFa in the depression-like behavior observed in our
experimental paradigm. For that purpose, we employed
TNFa p55 receptor-deficient mice. As TNFa p55 recep-
tor knockout animals used in the present study are C57/
BL6 inbred, we employed this mouse strain in this part
of the study. In C57/BL6 mice, a dose of 1000 μg/kg of
E. coli LPS was necessary to evoke a significant increase
in immobility time in the tail-suspension test, compar-
able to that obtained with a 450 μg/kg dose in CF1 mice
(about 1.5-fold in relation to saline-treated animals).
Strikingly, the depression-like behavior caused by forced
swimming plus LPS treatment (1000 μg/kg, i.p.) was vir-
tually abolished in mice with genetic deletion of TNFa
p55 receptors (Figure 5d). Of note, the increase of B1
receptor mRNA expression in mice submitted to forced
swimming plus LPS treatment was completely absent in
TNFa p55 receptor knockout animals (Figure 5e).
Discussion
During the last few years, several advances have been
achieved in our understanding of the genetic, biochem-
ical and immunological changes implicated in depres-
sion [35]. Concerning the immunological mechanisms,
certain pro-inflammatory cytokines, mainly IL-6, IL-1b
and TNFa, have been recently pointed out as pivotal
molecules for depression-related behaviors following
infection. These cytokines are likely able to coordinate
local and systemic inflammatory responses to pathogens
[2,22]. In the depression-like behavioral paradigm
employed herein, we demonstrate that administration of
LPS (450 μg/kg, i.p.) in mice previously submitted to a
5-min swimming session, produces earlier signals of
sickness behavior, such as decreased body temperature
and locomotor activity 6 h post-LPS, which are followed
by a later manifestation of depression-like behavior, i.e.
an increase of immobility time in the tail suspension
test, 24 h post-LPS. This is in line with literature data
indicating that sickness behavior represents a normal
initial response to infectious stimuli [33,36], although
depression-like states might persist after initial sickness
alterations have resolved [3,37].
To the best of our knowledge, there is no previous study
correlating kinin B1 receptors and depression. These
receptors are commonly absent under normal conditions
in the periphery, but might be rapidly up-regulated by
stressful stimuli. Interestingly, basal expression of B1
receptor has been described in spinal cord and some brain
structures, such as cerebral cortex, hippocampus, thala-
mus, hypothalamus, amygdala, and choroid plexus epithe-
lial cells [10,38,39]. Even though the exact role of kinins in
the brain is not clear, basal expression of B1 receptor in
the nervous system is compellingly suggestive of a central
role for these molecules [10,19,40]. Herein, we have
assessed whether B1 receptors might be implicated in the
depression-like behavior induced by LPS and pre-stressful
stimuli.
Figure 2 Expression of B1 receptor mRNA in hippocampus and
cortex of mice after acute inflammation. Time-related effects of a
5-min forced swimming session plus E. coli LPS treatment (450 μg/
kg, i.p.) on B1 receptor mRNA expression in the hippocampus (a)
and cortex (b) of mice. Each column represents the mean of 4
animals and vertical lines show the SEM. *P < 0.05 and **P < 0.01
compared to vehicle-treated mice.
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sion test was significantly reduced by the antidepressant
imipramine, in a dose which was effective in stressed
rodents [27]. Interestingly, the increased immobility was
significantly inhibited by treatment with either selective
B1 receptor antagonists R-715 or SSR240612. These
results are indicative of a relevant role for B1 receptors
in depression-like behavior. Our in vivo data were rein-
forced by real-time PCR experiments, which demon-
strated a marked increase in B1 receptor mRNA
expression in hippocampus, and notably, in the cortex
of mice submitted to forced swimming plus LPS admin-
istration. Alterations of hippocampal plasticity have
been widely demonstrated in depression associated with
stressful insults [32,40-42]. Nevertheless, the present
study is, to the best of our knowledge, the first demon-
stration that infection associated with a stressful
stimulus might up-regulate B1 receptors in the CNS,
leading to depressive behavior. Conversely, treatment of
mice with the selective B2 receptor antagonist FR173657
failed to significantly affect immobility time in our
depression paradigm. This is well aligned with the pro-
posed physiological roles of kinin B2 receptors [43].
Considering this paradigm, the participation of B2 recep-
tors was not further considered in the present study.
Of high interest, functional data obtained in the tail
suspension test was extended by results employing
the anhedonia paradigm of sucrose intake, in which
SSR240612 was able to completely reverse reduced
sucrose consumption in LPS-treated mice. It is well
known that depression is likely associated with anhedo-
nia states, where pleasure sensations are reduced or
even missing [29,44]. It is noteworthy that stressful
forced swimming plus LPS administration resulted in a
Figure 3 Microglial activation in the mouse hippocampus following acute inflammation; effect of B1 receptor antagonism.E f f e c to f
systemic administration of E. coli LPS (450 μg/kg, i.p., 24 h) on microglial activation (CD68-positivity) in the hippocampus of mice submitted to a
previous 5-min forced swimming session. Mice were treated with imipramine (10 mg/kg i.p.) or SSR240612 (5 mg/kg, i.p.), given 30 min
beforehand. (a) Representative image of CA1, CA2, CA3 and dentate gyrus (DG) subregions of hippocampus (Scale bar = 200 μm, original
magnification, × 40). (b) Graphic representation on the average number of CD68-positive cells per field, determined in the CA1, CA2, CA3, and
DG subregions of the hippocampus. (c) Representative images of CD68 immunohistochemistry in the DG subregion of hippocampus (Scale bar
=5 0μm, original magnification, × 400) from pre-stressed animals treated with E. coli LPS, following imipramine (10 mg/kg i.p.), SSR240612 (5
mg/kg, i.p., 30 min or 10 mg/kg, p.o., 1 h), or saline 30 min before. LPS treatment showed an increase in the number of CD68-positive cells (c,
arrows) in the hipocamppus, and SSR240612 (5 mg/kg, i.p., 30 min or 10 mg/kg, p.o., 1 h), was able to reduce this increase (c). Each column
represents the mean of 4 animals and the vertical lines show the SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to vehicle-treated mice.
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Page 8 of 12significant decrease in sucrose consumption in Swiss
mice, a parameter that was reversed by the antidepres-
sant imipramine, which reinforces the validity of our
experimental design [45]. On the other hand, sickness
behavior-induced hypothermia was not significantly
altered by the administration of the B1 receptor antago-
nist R-715. This evidence indicates that blocking B1
receptors is able to reverse later depression-like symp-
toms without interfering with early sickness behavior,
which seems to be coordinated mainly by cytokines [46].
The major immunocompetent components of the CNS
are represented by microglia and astrocytes, and the acti-
vation of these cells likely contributes to the pathogenesis
of depression [43,47,48]. Our data clearly demonstrate
that forced swimming followed by LPS treatment results
in activation of microglia in mice, as indicated by an
enhancement of CD-68 immunostaining in hippocampus
24 h after LPS injection, when B1 mRNA levels return to
basal. It has been demonstrated that microglial activation
in response to several kinds of injury drives the release of
neurotoxic mediators, such as pro-inflammatory cytokines
[3,49]. Of relevance, systemic treatment with the selective
non-peptide B1 receptor antagonist SSR240612 virtually
abolished the CD-68 immunopositivity, but notably this
parameter was not significantly altered by imipramine.
This allows us to suggest that antidepressant-like effects
of B1 receptor antagonists, but not that caused by
imipramine, are related to inhibition of microglial activa-
tion. These findings are quite relevant and open a new
avenue to understand depressive states, especially those
associated to infection.
Depression is clearly associated with synaptic plasticity
changes, resulting in decreased BDNF function, among
other biochemical alterations. It has been demonstrated
that under stressful conditions, the BDNF gene is
repressed leading to neuronal apoptosis in hippocampus
[40,50]. Of interest, BDNF infusion in some brain regions
induces antidepressant-like effects in animal models
[50-52]. Additionally, most monoaminergic antidepres-
sant drugs are known to restore normal BDNF transcrip-
tional levels [33-35,34]. Our depression model caused a
sustained reduction in BDNF mRNA expression in hip-
pocampus (up to 24 h). Of note, BDNF mRNA expres-
sion was not significantly altered by previous
administration of the selective B1 receptor antagonist
SSR240612. Therefore, although B1 receptor antagonism
prevented microglial activation, it failed to restore
decreased brain levels of BDNF. These results suggest
that SSR240612 seems to have an antidepressant-like
activity by acting through different mechanisms from
usual antidepressants; acting preferentially by an inflam-
matory pathway, and not by interfering with BDNF.
As mentioned above, pro-inflammatory cytokines are
deeply involved in the pathogenesis of depression [53,54].
Of note, patients with major depressive disorder have
increased expression of soluble TNFa receptors [55,56],
and patients under treatment with TNFa antagonists dis-
play a general improvement of depressive symptoms and
life quality [57,58]. Herein, we reinforce this hypothesis
by demonstrating that LPS administration in pre-stressed
mice results in a marked increase of TNFa levels in
serum, CSF and whole brain. TNFa production was initi-
ally augmented in serum (between 1 and 3 h), and later
increased in whole brain (between 3 and 6 h). Therefore,
it is possible to argue that increased TNFa levels in
serum are the main factor responsible for sickness beha-
vioral changes (i.e. hypothermia and reduced locomotor
activity), whereas the elevation of this cytokine in brain
underlies the depression-like behavior in the tail suspen-
sion test. In addition, multiplex cytokine analysis demon-
strated a marked increase of TNFa levels in CSF
obtained from LPS-treated mice (between 1 and 3 h),
although the levels of other cytokines remained unal-
tered. The presence of TNFa in the CSF supports the
idea of a communication pathway between the brain and
the immune system. When toll-like receptors on macro-
phage-like cells residing in the circumventricular recep-
tors are activated, they respond by producing pro-
inflammatory cytokines, such as TNFa [3]. As the cir-
cumventricular organs lie outside the blood-brain barrier
(BBB), and the BBB is relatively impermeable to
Figure 4 BDNF mRNA expression in hippocampus and cortex
of mice after acute inflammation; effects of B1 receptor
antagonism. Effect of systemic administration of E. coli LPS (450
μg/kg, i.p., 6 h and 24 h) on BDNF mRNA expression in the
hippocampus of mice submitted to a previous 5-min forced
swimming session, according to assessment by real-time PCR.
Influence of treatment with SSR240612 (5 mg/kg, i.p.), given 30 min
beforehand. Each column represents the mean of 4 animals and
vertical lines show the SEM. *P < 0.05 compared to vehicle-treated
mice.
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Page 9 of 12cytokines, the mechanisms by which circulating cytokines
might influence the brain function remain a matter of
debate [34]. One established theory is that they can enter
the brain by volume diffusion [3,58,58]. Cytokines might
additionally gain access to the brain through sites where
BBB is somewhat compromised, e.g. by stressful events
or immunologic challenges, such as those used in our
protocol [34]. Besides, kinins enhance permeability of
BBB. This would disturb BBB functioning, leading to var-
ious neuropathological conditions related to cytokine
entrance into the brain, including depression [59,60].
To gain further insights into the relevance of TNFa in
our experimental paradigm, we employed TNFa p55
receptor-KO mice. Both depression-like behavior and up-
regulation of B1 receptors induced by forced swimming
plus LPS treatment were virtually abolished in TNFa p55
receptor-KO mice. The relevance of TNFa for the up-reg-
ulation of B1 receptors has been described before by our
group [14-17]. The experimental evidence provided herein
clearly suggests a link between the cytokine TNFa and the
kinin B1 receptor upregulation in depression genesis.
The present data provide good evidence suggesting that
generation of this pro-inflammatory cytokine seems to
exert a critical role for LPS to induce B1 receptor upregu-
lation, as already demonstrated [14].
Most experts agree that depression should be viewed as
a syndrome, not a disease [60]. The current hypothesis
linking depression and the immune system suggests that
cytokines and other immune mediators work as ‘’sensor’’
molecules, capable of transforming noncognitive stimuli
(i.e. inflammatory process) into cognitive stimuli, allow-
ing the CNS to recognize them, and to elaborate an inte-
grated response to the peripheral event. Therefore,
molecules released during peripheral inflammatory
events may influence central factors controlling homeos-
tasis and behavior [58,59]. Our findings bring a new
Figure 5 TNFa levels in serum and brain of mice following acute inflammation; relevance of TNFa p55 receptor for B1 receptor mRNA
expression. Time-related effects of treatment with LPS (450 μg/kg, i.p.) on TNFa levels in serum (a), whole brain (b) or CSF (c) of CF1 mice,
submitted to a previous 5-min forced swimming session, according to assessment by ELISA sandwich (a, b) or CBA (c) assays. (d) Effect of
systemic administration of E. coli LPS (1000 μg/kg i.p., 24 h) on immobility time, in C57/BL6 or TNFa p55 receptor knockout mice, as assessed in
the tail suspension test. (e) Evaluation of B1 receptor mRNA expression in C57/BL6 or TNFa p55 receptor knockout mice that had been
previously submitted to a 5-min swimming section, and were pre-treated with E. coli LPS (1000 μg/kg i.p., 1 h). Each column represents the
mean of 6-8 animals and vertical line show the SEM. *P < 0.05, **P < 0.01 compared to naive or vehicle-treated mice and
##P < 0.01 compared
to C57BL/6 mice.
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Page 10 of 12piece of evidence into the depression disorder puzzle
which may help to understand its etiology: kinin B1
receptors might exert a critical role in affective disorders,
such as depression. The participation of B1 receptors in
depressive alterations seems to be related to microglial
activation, an event that seems to be associated with the
subsequent production of TNFa in the brain. It is tempt-
ing to suggest that a clinical trial with orally available
selective B1 receptor antagonists should be performed to
evaluate whether or not these molecules could help treat-
ing clinical symptoms of depression.
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